Skip to search formSkip to main contentSkip to account menu

NCO 700

Known as: NCO-700 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Piperazines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1990
1990
-0610-EFFECT OF MEMBRANE-PERMEABLE CYSTEINE PROTEASE INHIBITOR, NCO-700, ON SEROTONIN RELEASE FROM HUMAN PLATELETS (PLT)
1986
1986
Suppression of myocardial protein degradation by the protease inhibitor bis[ethyl(2R,3R)-3-[(S)-methyl-1-[4-(2,3,4-tri-methoxy-phenyl-methyl) piperazine-1-ylcarbonyl]butyl-carbonyl]oxiran-2…
The synthetic protease inhibitor bis[ethyl(2R,3R)-3-[(S)-methyl-1-[4-(2,3,4-tri-methoxyphenyl-methyl) piperazine-1-ylcarbonyl… 
1986
1986
Temporary salvage of ischemic myocardium by the protease inhibitor bis[ethyl(2R,3R)-3-[(S)-methyl-1-[4-(2,3,4-trimethoxyphenyl-methyl) piperazin-1-ylcarbonyl]butyl-carbonyl]oxiran-2-carbo xylate…
The administration (i.v., 20, 40 and 60 mg/kg) of the thiol protease inhibitor bis[ethyl(2R, 3R)-3-[(S)-methyl-1-[4-(2,3,4… 
1985
1985
Effect of NCO-700, an inhibitor of protease, on myocardial pH decreased by coronary occlusion in dogs.
During myocardial ischemia in dogs effects of NCO-700, a protease inhibitor on myocardial pH, were investigated. Ischemia was… 
1983
1983
EFFECT OF A SYNTHETIC PROTEASE INHIBITOR, NCO-700, ON THE DEGRADATION OF MYOCARDIAL PROTEINS IN VITRO AND THE SALVAGE OF ISCHEMIC MYOCARDIUM IN VIVO : PROCEEDINGS OF THE 47th ANNUAL SCIENTIFIC…
1982
1982
Reduction of experimentally produced acute myocardial infarction size by a new synthetic inhibitor, NCO-700, against calcium-activated neutral protease.
Calcium-activated neutral protease (CANP) might be involved in the irreversible degradation of myocardial proteins in the…